Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19165892rdf:typepubmed:Citationlld:pubmed
pubmed-article:19165892lifeskim:mentionsumls-concept:C0017638lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C0796392lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C0123931lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C0018017lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C2911648lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C1571702lld:lifeskim
pubmed-article:19165892lifeskim:mentionsumls-concept:C1719797lld:lifeskim
pubmed-article:19165892pubmed:issue7lld:pubmed
pubmed-article:19165892pubmed:dateCreated2009-4-13lld:pubmed
pubmed-article:19165892pubmed:abstractTextChemotherapy has taken on a prominent role in the treatment of pediatric low-grade gliomas not amenable to gross total resections; however, there are few proven effective options for children with multiply recurrent tumors. Bevacizumab, a humanized immunoglobulin, monoclonal antibody that inhibits the activity of vascular endothelial growth factor and irinotecan have been used with some success in adults with malignant gliomas.lld:pubmed
pubmed-article:19165892pubmed:languageenglld:pubmed
pubmed-article:19165892pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19165892pubmed:citationSubsetIMlld:pubmed
pubmed-article:19165892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19165892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19165892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19165892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19165892pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19165892pubmed:statusMEDLINElld:pubmed
pubmed-article:19165892pubmed:monthJullld:pubmed
pubmed-article:19165892pubmed:issn1545-5017lld:pubmed
pubmed-article:19165892pubmed:authorpubmed-author:PackerRoger...lld:pubmed
pubmed-article:19165892pubmed:authorpubmed-author:CohenBruceBlld:pubmed
pubmed-article:19165892pubmed:authorpubmed-author:VezinaGilbert...lld:pubmed
pubmed-article:19165892pubmed:authorpubmed-author:FisherMichael...lld:pubmed
pubmed-article:19165892pubmed:authorpubmed-author:JakackiRegina...lld:pubmed
pubmed-article:19165892pubmed:authorpubmed-author:RoodBrianBlld:pubmed
pubmed-article:19165892pubmed:authorpubmed-author:MacDonaldTobe...lld:pubmed
pubmed-article:19165892pubmed:authorpubmed-author:HornMariannaMlld:pubmed
pubmed-article:19165892pubmed:copyrightInfo(c) 2009 Wiley-Liss, Inc.lld:pubmed
pubmed-article:19165892pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19165892pubmed:volume52lld:pubmed
pubmed-article:19165892pubmed:ownerNLMlld:pubmed
pubmed-article:19165892pubmed:authorsCompleteYlld:pubmed
pubmed-article:19165892pubmed:pagination791-5lld:pubmed
pubmed-article:19165892pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:meshHeadingpubmed-meshheading:19165892...lld:pubmed
pubmed-article:19165892pubmed:year2009lld:pubmed
pubmed-article:19165892pubmed:articleTitleObjective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.lld:pubmed
pubmed-article:19165892pubmed:affiliationDivision of Neurology, Children's National Medical Center, Washington, District of Columbia 20010, USA. rpacker@cnmc.orglld:pubmed
pubmed-article:19165892pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19165892pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19165892lld:pubmed